The efficacy and safety of Crataegus extract WS® 1442 in patients with heart failure: The SPICE trial
The efficacy and safety of Crataegus extract WS® 1442 in patients with heart failure: The SPICE trial
复制标题
DOI：
10.1016/j.ejheart.2008.10.004
复制
发表时间：
2008-12-01
影响因子：
18.2
通讯作者：
Tendera, Michal
中科院分区：
文献类型：
--
作者：
Holubarsch, Christian J. F.;Coucci, Wilson S.;Tendera, Michal
Background: Crataegus preparations have been used for centuries especially in Europe, To date, no proper data oil their efficacy and safety as an add-on-treatment are available. Therefore a large morbidity/mortality trial was performed.Aim: To investigate the efficacy and safety of an add-on treatment with Crataegus extract WS (R) 1442 in patients with congestive heart failure.Methods: In this randomised, double-blind, placebo-controlled multicenter study, adults with NYHA class II or III CHF and reduced left ventricular ejection fraction (LVEF = 25%, WS (R) 1442 reduced sudden cardiac death by 39.7% (HR 0.59 [0.37;0.94] at month 24; p = 0.025). Adverse events were comparable in both groups.Conclusions: In this study, WS (R) 1442 had no significant effect on the primary endpoint. WS (R) 1442 was safe to use in patients receiving optimal medication for heart failure. In addition, the data may indicate that WS (R) 1442 can potentially reduce the incidence of sudden cardiac death, at least in patients with less compromised left ventricular function, (C) 2008 European Society of Cardiology. Published by Elsevier B.V. All rights reserved.
